Evidence map›Paper›PMID 20485670›Full record

ArticlePloS one2010

Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors.

Man Charurat, Modupe Oyegunle, Renata Benjamin, Abdulrazaq Habib, Emeka Eze, Prince Ele, Iquo Ibanga, Samuel Ajayi, Maria Eng, Prosanta Mondal and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 6 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 6 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. User-centered adaption ofAIDS care · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Man CharuratInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America. mcharurat@ihv.umaryland.edu
Modupe Oyegunle
Renata Benjamin
Abdulrazaq Habib
Emeka Eze
Prince Ele
Iquo Ibanga
Samuel Ajayi
Maria Eng
Prosanta Mondal
Usman Gebi
Emilia Iwu
Mary-Ann Etiebet
Alash'le Abimiku
Patrick Dakum
John Farley
William Blattner
University of Maryland, Baltimore · USInstitute of Human Virology · NGAminu Kano Teaching Hospital · NGNnamdi Azikiwe University Teaching Hospital · NGUniversity of Abuja · NGUniversity of Benin Teaching Hospital · NGUniversity of Calabar · NG

Funding

HIV/AIDS Prevention, Care and Treatment in the Federal Republic of NigeriaU2GPS000651 · PS · UNIVERSITY OF MARYLAND BALTIMORE · PI BLATTNER, WILLIAM ALBERT · 2006 to 2010
$201.0M
WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
UM-IHV AITRP in NigeriaD43TW001041 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E · 1998 to 2015
$9.2M
FIC NIH HHS D43 TW001041NCHHSTP CDC HHS PS000651NIAID NIH HHS U01 AI069919NIAID NIH HHS U01AI069919
6 · The paper itself

Abstract

backgroundSubstantial resources and patient commitment are required to successfully scale-up antiretroviral therapy (ART) and provide appropriate HIV management in resource-limited settings. We used pharmacy refill records to evaluate risk factors for loss to follow-up (LTFU) and non-adherence to ART in a large treatment cohort in Nigeria. METHODS AND

findingsWe reviewed clinic records of adult patients initiating ART between March 2005 and July 2006 at five health facilities. Patients were classified as LTFU if they did not return >60 days from their expected visit. Pharmacy refill rates were calculated and used to assess non-adherence. We identified risk factors associated with LTFU and non-adherence using Cox and Generalized Estimating Equation (GEE) regressions, respectively. Of 5,760 patients initiating ART, 26% were LTFU. Female gender (p < 0.001), post-secondary education (p = 0.03), and initiating treatment with zidovudine-containing (p = 0.004) or tenofovir-containing (p = 0.05) regimens were associated with decreased risk of LTFU, while patients with only primary education (p = 0.02) and those with baseline CD4 counts (cell/ml(3)) >350 and <100 were at a higher risk of LTFU compared to patients with baseline CD4 counts of 100-200. The adjusted GEE analysis showed that patients aged <35 years (p = 0.005), who traveled for >2 hours to the clinic (p = 0.03), had total ART duration of >6 months (p<0.001), and CD4 counts >200 at ART initiation were at a higher risk of non-adherence. Patients who disclosed their HIV status to spouse/family (p = 0.01) and were treated with tenofovir-containing regimens (p < or = 0.001) were more likely to be adherent.

conclusionsThese findings formed the basis for implementing multiple pre-treatment visit preparation that promote disclosure and active community outreaching to support retention and adherence. Expansion of treatment access points of care to communities to diminish travel time may have a positive impact on adherence.

Indexed as

Antiretroviral Therapy, Highly ActivePatient ComplianceAdultAnti-Retroviral AgentsFemaleFollow-Up StudiesHIV InfectionsHumansLongitudinal StudiesMaleMedication AdherenceNigeriaPharmaciesProportional Hazards ModelsRegression AnalysisRisk FactorsAnti-Retroviral Agents

Identifiers

PMID20485670
PMCPMC2868044
OpenAlexW2058699555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.